Compared to the beginning of the month, the 14 stocks tracked in G-2’s Laboratory Stock Index were down 17 percent when the market closed on Monday, June 30. The publicly traded lab ending the month with the top gain was Enzo Clinical Laboratories (New York City), up 19% to $11.22 per share for a market cap of $423.21 million for the month ended Jun. 30. Coming in behind Enzo was Genoptix (San Diego), up 14 percent to $31.55 per share for a market cap of $507.45 million. The two labs leading in losses over the month were Bio-Reference Laboratories (Elmwood Park, N.J.) and Orchid Cellmark (Princeton, N.J.), both down 11 percent for the month ended Jun. 30. Bio-Reference closed out the month at $22.31 per share and a market cap of $302.28 million, while Orchid ended June at $2.60 per share and a market cap of $80.91 million. The molecular diagnostic laboratory Neogenomics (Ft. Myers, Fla.) also lead in losses. Its stock was down 8 percent by the end of the month to $1.20 per share for a market cap of $36.07 million. (Note: all market cap figures were accessed at approximately 10:00am on Tuesday, July 1.) For continuous coverage of these and other publicly traded laboratories, visit www.g2reports.com, and visit the G-2 Laboratory Stock Index section of the Web site.